a lot of stuff, page-34

Istari

I know this is a PRR thread, but in the interest of info relating to potential competition, then it is worth noting here.

I agree that despite the apparent lack of drive now to get Novogen's to date lead drug through the rest of phase III trials, from the 10 minute interview I watched with their CEO Alan Husband, I was markedly impressed with the reasons why they dropped it which basically hinges around the huge excitement they have for NV128, which as you say seems to be taking a whole new approach to tackling cancer.

Don't ask me to explain it, watch the interview - it's interesting.

Important thing to note is that tests have so far only been done on animals so they are at very early stage of drug development, even though the results so far are very exciting for Novogen.

I too believe that Novogen may well come up trumps with NV128 and it will likely give a number of successful drugs a run for their money. Whilst there is longer term competition here fro PRR, Novogen's NV128 is a good number of years from going to market, so PRR have a good chance to reapo significant rewards until then once it gets to market (not to mention their pipeline possibilities that will likely emerge after CVac).

http://www.youtube.com/watch?v=TDJvmufWtkY

Cheers